Asset profile
Tofersen · Qalsody
RNA / oligonucleotide
Evidence outlook
Approved: Amyotrophic Lateral Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tofersen (Qalsody): this drug | Approved | RNA / oligonucleotide | — | ||
| AV411 | Phase 3 | Small molecule | PDE4 and PDE10; macrophage migration inhibitory factor (MIF) | ||
| Ulefnersen | Phase 3 | RNA / oligonucleotide | — | ||
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | ||
| Dazucorilant | Phase 2 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
August 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.